The industry's claimed 'surprised' over the government's approach to the implementation, notably the 'double dipping' on statutory price reductions, appears to confront the significant challenge that it was warned of the risk last year but dismissed any concern.
The industry was warned last year but dismissed the risk of 'double dipping' on April reductions
October 10, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer
October 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 October
October 17, 2025 - - Podcast -
New partnership aims to strengthen local cell and gene manufacturing capability
October 16, 2025 - - Australian Biotech -
Vertex announces New Zealand registration of next-generation cystic fibrosis treatment
October 16, 2025 - - Latest News -
Lilly’s oral GLP-1 therapy delivers strong results in late-stage diabetes trials
October 16, 2025 - - Latest News -
NDIS participant numbers and spending continue growth trajectory in latest quarterly data
October 15, 2025 - - Other Health -
Key Pharmaceuticals builds on a 40-year legacy to support frontline health
October 15, 2025 - - Latest News